Navigation Links
FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals' Lead Product Candidate OGX-011
Date:8/22/2008

OGX-011 treatment can significantly reduce serum clusterin levels and that achieving low serum clusterin levels during treatment is correlated with improved survival. Furthermore, serum clusterin levels during OGX-011 treatment may be predictive of a treatment benefit with OGX-011. In patients with HRPC who had failed first-line docetaxel while on or within six months of first-line docetaxel therapy and received second-line chemotherapy in combination with OGX-011 (Study OGX-011-07), achieving or maintaining low serum clusterin levels correlated with improved survival. Similar results were seen in Study OGX-011-05 in patients with NSCLC who were treated with gemcitabine plus a platinum regimen and OGX-011. Data from the Phase 2 study in HRPC were presented at the 2008 Annual Meeting of the American Society of Clinical Oncology.

About OncoGenex Pharmaceuticals

OncoGenex Pharmaceuticals is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate currently completing five Phase 2 clinical studies in prostate, lung and breast cancers, is designed to inhibit the production of specific proteins associated with treatment resistance; OGX-427 and SN2310 are in Phase 1 clinical development; and CSP9222 and OGX-225 are currently in pre-clinical development. More information is available at http://www.oncogenex.com.

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements concerning Fast Track Designation for OGX-011 and anticipated clinical and other product development activities and
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. GlaxoSmithKline To Post Quarterly US Grants Report
2. FDA Grants Full Approval of PROCLEIX(R) ULTRIO(R) Blood Screening Assay
3. FDA Grants Epeius Biotechnologies Rexin-G a Third Orphan Drug Designation, This Time for the Treatment of Soft Tissue Sarcomas
4. US FDA Grants Pediatric Exclusivity for UCBs Keppra(R)
5. Xceed Molecular Grants Gen-Probe License to Xceeds Flow-Thru Chip(R) Technology for Multiplex Molecular Diagnostics
6. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
7. Intellect Neurosciences, Inc. Grants License for Certain Patents and Patent Applications to Wyeth and Elan Pharma International Ltd.
8. Lentigen Corporation Receives Four Research Grants From the National Institutes of Health
9. Susan G. Komen for the Cure(R) Announces Largest Grants Slate Ever: $100 Million to Speed Delivery of Breast Cancer Discoveries, Cures
10. European Union, State of Brandenburg, Award Grants to Alcat Europe, GmbH
11. FDA Grants Market Clearance to Aerocrine Inc.s NIOX MINO(R): a New Hand-Held Device to Measure Airway Inflammation in Asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Diego, CA (PRWEB) January 14, 2014 ... on the products of cells grown under simulated embryonic ... international license agreement with Suneva Medical, Inc. for physician-dispensed ... (CCM). , This agreement is an amendment ...
(Date:1/14/2014)... , Jan. 14, 2014 As pet owners drew up ... many of them wrote: "Take better care of my furry companion." ... designer clothes and top-brand carrying cases to take the little canine ... might also feel compelled to buy some pricey toys at the ...
(Date:1/14/2014)... 14, 2014 The largest international professional organization ... and therapeutic derivatives thereof has endorsed an educational ... about the challenges of adulterated herb and botanical ... The Society for Medicinal Plant and ...
(Date:1/14/2014)... 14, 2014 iLab Solutions, the leader in ... new Director of Product Strategy. In this role, Michelle will ... sub-teams to guide in the development of iLab products. Her ... maximum possible benefit to the scientific community by offering the ...
Breaking Biology Technology:Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2
... - Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced ... pursue a pivotal (Phase II/III) randomized trial ... refractory,patients with head and neck cancers. The ... by the Company,s Board of Directors from ...
... team up in specialty biologics development, TORONTO ... and,Therapure BioPharma Inc. have agreed to partner in ... for cancer treatments, with a goal of,advancing the ... a,marketing partner to add to its portfolio of ...
... deCODE,genetics (Nasdaq: DCGN ) today announced today that ... Qualifications Panel to present a plan for,regaining compliance ... market value of listed securities of $50 million. ... Letter from The,Nasdaq Stock Market LLC indicating that ...
Cached Biology Technology:Oncolytics Biotech Inc. Announces Decision to Pursue Phase II/III Pivotal Clinical Trial 2Therapure Biopharma Inc. announces collaboration with BioVectra Inc. 2deCODE Requests Hearing With Nasdaq Following Receipt of Staff Determination Letter 2deCODE Requests Hearing With Nasdaq Following Receipt of Staff Determination Letter 3deCODE Requests Hearing With Nasdaq Following Receipt of Staff Determination Letter 4
(Date:4/17/2014)... RIVERSIDE, Calif. One day about eight years ago, ... of California, Riverside, and her father were on a field ... stumbled upon an orchid they had never seen before. , ... authority on orchids. The orchid turned out to be ... Silveras: Lophiaris silverarum . , "Lophiaris" is the genus ...
(Date:4/17/2014)... in France have hit on a novel method ... the correct and most effective treatment possible., Kidney ... western and developing world. If left untreated, apart ... renal failure and other complications. In many patients ... Clearly a more effective pathological approach to diagnosis ...
(Date:4/17/2014)... whereby the genetic information of DNA is used ... have numerous different functions in living organisms. Messenger ... gene expression, by relating the genetic information of ... proteins. , By examining the different types ... organism at a given time, researchers can determine ...
Breaking Biology News(10 mins):Orchid named after UC Riverside researcher 2Orchid named after UC Riverside researcher 3Rapid and accurate mRNA detection in plant tissues 2
... discovery by researchers at Oregon State University, the world,s multi-billion ... This industry, that produces metal castings used in everything from ... dates back thousands of years to before Greek and Roman ... but still continues to evolve. Some modern technologies use ...
... sites across the U.S. have contaminated groundwater that requires remediation, ... meaning restoration is unlikely to be achieved in the next ... new report from the National Research Council. The report ... sites ranges from $110 billion to $127 billion, but the ...
... becomes increasingly important to know in detail the dynamics of ... of a millimeter). What happens, for example, when we try ... molecules, such as DNA) through a nanopore if knots cause ... because now a new DNA sequencing method to electrochemically analyze ...
Cached Biology News:Sweet new approach discovered to help produce metal casting parts, reduce toxicity 2Report: Cleanup of some contaminated groundwater sites unlikely for decades 2Report: Cleanup of some contaminated groundwater sites unlikely for decades 3Pull with caution 2
Although each Beacon 2000 System includes one preinstalled sample chamber (size specified at time of order), optional chambers are available and easily retrofit by the user....
... Immunogen : Recombinant human ... 5mg/ml BSA, 0.15M NaCl, 0.05% ... of glycerol to 30% Quality ... on acid extracts of murine ...
cDNA Size Fractionation Columns offer an efficient and convenient method for size-fractioning double-stranded cDNA....
Self Closing Forceps...
Biology Products: